JP2019524829A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524829A5 JP2019524829A5 JP2019508812A JP2019508812A JP2019524829A5 JP 2019524829 A5 JP2019524829 A5 JP 2019524829A5 JP 2019508812 A JP2019508812 A JP 2019508812A JP 2019508812 A JP2019508812 A JP 2019508812A JP 2019524829 A5 JP2019524829 A5 JP 2019524829A5
- Authority
- JP
- Japan
- Prior art keywords
- carbamoyl
- oxo
- octane
- formula
- hydrogen sulfate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 159000000000 sodium salts Chemical class 0.000 claims 3
- 238000001157 Fourier transform infrared spectrum Methods 0.000 claims 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 150000007513 acids Chemical class 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 229910003460 diamond Inorganic materials 0.000 claims 2
- 239000010432 diamond Substances 0.000 claims 2
- -1 octane-6-yl Chemical group 0.000 claims 2
- 150000007524 organic acids Chemical class 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 claims 1
- ORFOPKXBNMVMKC-DWVKKRMSSA-N ceftazidime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-N 0.000 claims 1
- 229960000484 ceftazidime Drugs 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 229910017604 nitric acid Inorganic materials 0.000 claims 1
- 235000005985 organic acids Nutrition 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 1
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 1
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 1
- VYPDUQYOLCLEGS-UHFFFAOYSA-M sodium;2-ethylhexanoate Chemical compound [Na+].CCCCC(CC)C([O-])=O VYPDUQYOLCLEGS-UHFFFAOYSA-M 0.000 claims 1
- 239000002132 β-lactam antibiotic Substances 0.000 claims 1
- 229940124586 β-lactam antibiotics Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16185913.7 | 2016-08-26 | ||
| EP16185913 | 2016-08-26 | ||
| PCT/EP2017/071471 WO2018037124A1 (en) | 2016-08-26 | 2017-08-25 | Avibactam free acid |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019524829A JP2019524829A (ja) | 2019-09-05 |
| JP2019524829A5 true JP2019524829A5 (enExample) | 2020-09-10 |
| JP7183147B2 JP7183147B2 (ja) | 2022-12-05 |
Family
ID=56802364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019508812A Active JP7183147B2 (ja) | 2016-08-26 | 2017-08-25 | アビバクタム遊離酸 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11124513B2 (enExample) |
| EP (1) | EP3504207B1 (enExample) |
| JP (1) | JP7183147B2 (enExample) |
| KR (1) | KR102482826B1 (enExample) |
| CN (1) | CN109641901B (enExample) |
| AU (1) | AU2017315164B2 (enExample) |
| CA (1) | CA3034470A1 (enExample) |
| WO (1) | WO2018037124A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110267956B (zh) | 2017-02-08 | 2022-07-15 | 桑多斯股份公司 | 用于制备阿维巴坦钠结晶形式c的方法 |
| CN113105455B (zh) * | 2020-01-10 | 2024-05-17 | 四川科伦药物研究院有限公司 | 晶型b阿维巴坦钠的制备方法 |
| CN115677697B (zh) * | 2022-09-19 | 2024-08-06 | 瑞阳制药股份有限公司 | 粒度可调控且流动性好的b晶型阿维巴坦钠析晶方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2812635B1 (fr) | 2000-08-01 | 2002-10-11 | Aventis Pharma Sa | Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens |
| FR2951171A1 (fr) | 2009-10-09 | 2011-04-15 | Novexel | Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation |
| BR112013032415B1 (pt) | 2011-06-17 | 2021-07-27 | Pfizer Anti-Infectives Ab | Processos para preparar compostos e compostos |
| CN105143226A (zh) | 2013-03-08 | 2015-12-09 | 沃克哈特有限公司 | 制备(2s,5r)-2-甲酰胺基-7-氧代-6-磺酰氧基-1,6-二氮杂-双环[3.2.1]辛烷的钠盐的方法 |
| CA2962540A1 (en) * | 2014-09-25 | 2016-03-31 | Manu Chaudhary | Stealth, targeted nanoparticles (stn) for oral drug delivery |
| US10265326B2 (en) | 2015-08-10 | 2019-04-23 | Sandoz Ag | Form C of avibactam sodium |
| CN106699756B (zh) * | 2016-12-30 | 2019-10-29 | 淄博鑫泉医药技术服务有限公司 | β内酰胺酶抑制剂阿维巴坦的合成方法 |
-
2017
- 2017-08-25 WO PCT/EP2017/071471 patent/WO2018037124A1/en not_active Ceased
- 2017-08-25 CA CA3034470A patent/CA3034470A1/en not_active Abandoned
- 2017-08-25 US US16/328,117 patent/US11124513B2/en active Active
- 2017-08-25 EP EP17758148.5A patent/EP3504207B1/en active Active
- 2017-08-25 AU AU2017315164A patent/AU2017315164B2/en active Active
- 2017-08-25 KR KR1020197008169A patent/KR102482826B1/ko active Active
- 2017-08-25 CN CN201780052135.4A patent/CN109641901B/zh active Active
- 2017-08-25 JP JP2019508812A patent/JP7183147B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014524442A5 (enExample) | ||
| JP2014500861A5 (enExample) | ||
| IL318601A (en) | Improved synthesis of a key intermediate of the KRAS inhibitor compound G12C | |
| JP2013538849A5 (enExample) | ||
| JP2009143956A5 (enExample) | ||
| RU2014110399A (ru) | Кристаллические формы вгс протеазного ингибитора | |
| JP2010530897A5 (enExample) | ||
| ES2613716T3 (es) | Formas cristalinas de un derivado de purina | |
| JP2013503119A5 (enExample) | ||
| WO2008121634A3 (en) | Nucleoside phosphoramidate prodrugs | |
| JP2019524829A5 (enExample) | ||
| JP2015501820A5 (enExample) | ||
| JP2017531038A5 (enExample) | ||
| JP2016190843A5 (enExample) | ||
| JP2021530565A5 (enExample) | ||
| JP2013515037A5 (enExample) | ||
| JP2012513416A5 (enExample) | ||
| JP2015509973A5 (enExample) | ||
| JP2016529195A5 (enExample) | ||
| RU2017123112A (ru) | Способ производства кристаллов производного диазабициклооктана и стабильного лиофилизированого препарата | |
| JP2015522037A5 (enExample) | ||
| JP2014530818A5 (enExample) | ||
| JP2016513060A5 (enExample) | ||
| JP2013520488A5 (enExample) | ||
| JP2014524449A5 (enExample) |